Cut through the noise.
Trade on the signal.
A weekly synthesis of institutional-grade financial reports and market mechanics.
No spam. Unsubscribe anytime.
Latest Reports
12 of 180 reportsZSTK: Fake Cannabis Utopia to Worthless Meme Coin Buffoonery – Fugazi Research
Fugazi Research says ZeroStack's token treasury has collapsed 91%, triggering going-concern risk and heavy dilution.
Making sense of Sandisk’s long-term financial model – Bristlemoon Capital
Bristlemoon Capital says Sandisk's 80% margin model depends on NAND prices falling to contract floors below current levels.
SELLAS Life Sciences ($SLS): The “Doctor,” the Death Clock, and the $3 Billion Delusion – BMF Reports
BMF Reports questions SELLAS's REGAL power claims, dilution, and valuation ahead of the Phase 3 overall-survival readout.
NEW: Magic Johnson’s Life Insurer Backed Magic Johnson’s Investment Fund — and a Dodgers TV Deal – HUNTERBROOK
Hunterbrook Media says EquiTrust hid related-party ties in $350M Dodgers debt and a $100M+ Johnson-Holoman fund stake.
XHLD: A Shady Underwriter’s Pump & Dump on the Brink of T-12 Halting – Fugazi Research
Fugazi Research says TEN Holdings sent 61% of IPO cash to empty deals amid DOJ and SEC probes, dilution, and heavy losses.
BREAKING: Modine’s Anchor Multi-Billion Dollar Customers Are Google and Amazon – HUNTERBROOK
Hunterbrook Media says an exposed Modine database reveals Google and AWS data-center cooling demand and supplier bottlenecks.
AEVA: Ridiculous Valuation for a Bleeding Startup Masquerading as AI – Fugazi Research
Fugazi Research says Aeva is overvalued at 72x sales as insiders sold into an AI-optics rally and losses keep mounting.
PMV Pharma: Making p53 Druggable? $pmvp – Two Natural Cap
Two Natural Capital says PMV Pharma's PMVP peak-sales math for rezatapopt is unrealistic despite ovarian cancer response data.
Exclusive: Walter and TWG Global Likely Can’t Use CVNA for Liquidity. Citi Already Secured It. – HUNTERBROOK
Hunterbrook says Citi’s lien still covers Mark Walter’s pledged Carvana stake, complicating any potential sale of CVNA shares.
NEW: Sammons announces ongoing Guggenheim divestment – HUNTERBROOK
Hunterbrook Media reports Sammons is divesting from Guggenheim amid conflicting control filings, a federal probe, and market fallout.
Capricor Therapeutics (NASDAQ: $CAPR): Turned a Rare Disease Into an Insider ATM – BMF Reports
BMF Reports says Capricor's Nippon deal was a non-binding LOI, with insider sales, stalled DMD trials, and grant-funded dilution.
Guggenheim’s Quiet Owner: $130B Insurance Giant Dodges Walter Drama Tied to Lakers Sale – HUNTERBROOK
Hunterbrook examines Sammons insurers’ Guggenheim ties, reclassification of related-party holdings, and Walter-linked exposure.